Last reviewed · How we verify
insulin glargine [rDNA origin] injection
Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | insulin glargine [rDNA origin] injection |
|---|---|
| Sponsor | Sanofi |
| Drug class | Long-acting basal insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin glargine is a recombinant human insulin analog engineered to have an extended duration of action (up to 24 hours). It binds to the insulin receptor on target tissues (muscle, fat, liver) to facilitate glucose transport into cells and promote glycogen synthesis while inhibiting gluconeogenesis. This provides steady, basal insulin coverage for patients with diabetes mellitus.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- insulin glargine [rDNA origin] injection CI brief — competitive landscape report
- insulin glargine [rDNA origin] injection updates RSS · CI watch RSS
- Sanofi portfolio CI